Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,575.83
(
-0.74%
)
US TECH 100
23,615.20
(
-0.76%
)
Dow Jones
45,802.76
(
-0.91%
)
Brent Oil
105.66
(
-0.87%
)
Bitcoin
69,705.47
(
-2.16%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 60469

Thursday, 09/25/2008 1:27:51 AM

Thursday, September 25, 2008 1:27:51 AM

Post# of 257259
>RDEA – They are also testing 806 (phase-2a) in gout syndrome because it showed reduction of uric acid in healthy people…<

RDEA806 will be dropped as a treatment for gout in favor of RDEA594 as soon as the phase-2a study in progress is completed. 594 is a metabolite of 806 that has no antiviral activity; it will presumably have a better safety and tolerability profile.

>…but I can't figure out the mechanism.<

The MoA in gout is blocking the URAT1 transporter.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now